JRCT ID: jRCT2041220056
Registered date:18/08/2022
Phase II, Open-label, Randomized, Multiple Ascending Dose Confirmation of the Safety and Tolerability of Brincidofovir in Subjects With BK Virus Infection (Viremia) After Kidney Transplantation
Basic Information
Recruitment status | Recruiting |
---|---|
Health condition(s) or Problem(s) studied | BK virus infection (viremia) after kidney transplantation |
Date of first enrollment | 31/10/2022 |
Target sample size | 36 |
Countries of recruitment | Australia,Japan,South Korea,Japan |
Study type | Interventional |
Intervention(s) | The study is composed of a Dose Escalation Phase and an Expansion Phase. A total of approximately 36 male or female subjects aged 18 years and older will be enrolled: 8 subjects (BCV: 6 subjects; SOC: 2 subjects) in each of 2 cohorts in the Dose Escalation Phase and 20 subjects (BCV: 14 subjects; SOC: 6 subjects) in the Expansion Phase. Dose Escalation Phase: - Cohort 1: BCV 0.3 mg/kg twice weekly - Cohort 2: BCV 0.4 mg/kg twice weekly - SOC: Immunosuppression reduction and monitoring Expansion Phase: - BCV: Recommended dosage regimen in the Dose Escalation Phase - SOC: Immunosuppression reduction and monitoring |
Outcome(s)
Primary Outcome | Safety Endpoints: - Incidence of treatment-emergent adverse events (TEAEs), particularly those of the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Grade 3 severity and serious adverse events - Incidence of treatment-related TEAEs - Incidence of adverse events (AEs) requiring permanent discontinuation of BCV - Absolute and changes over time in safety laboratory parameters (ie, hematology, blood chemistry, and urinalysis) Antiviral Effects Endpoints: - Change from baseline in BK viral load in plasma measured through follow-up for each subject - Change from baseline in BK viral load in urine measured through follow-up for each subject - Peak BK viral load in plasma from Week 2 Day 1 through follow-up for each subject - Time-averaged area under the viremia-time curve for BK viral load in plasma from baseline through follow-up for each subject |
---|---|
Secondary Outcome |
Key inclusion & exclusion criteria
Age minimum | >= 18age old |
---|---|
Age maximum | Not applicable |
Gender | Both |
Include criteria | 1. Male or female, at least 18 years of age at the time of signing the informed consent at screening. 2. Kidney transplant recipient. 3. "BK viral load increase and >= 3.6 log IU/mL" at 2 weeks post immunosuppression reduction or "BK viral load does not decrease by >= 0.3 log IU/mL" at 4 weeks post immunosuppression reduction during prescreening. (Note: Immunosuppressant reduction needs to be continued during the screening period). 4. eGFR >= 30 mL/min. 5. Subjects under immunosuppression with tacrolimus, MMF/Myfortic, and/or corticosteroid. |
Exclude criteria | 1. Subjects who weigh >= 120 kg. 2. National Institutes of Health/NCI CTCAE Grade 2 or higher diarrhea (ie, increase of >= 4 stools per day over usual pretransplant stool output) within 7 days before Day 1. 3. Poor clinical prognosis, including active malignancy or use of vasopressors other than low dose (eg, =< 5 ug/kg/min) dopamine for renal perfusion within 7 days before Day 1. 4. Use of renal replacement therapy within 7 days before Day 1. 5. History of intolerance to cidofovir or related compounds (ie, other nucleotide derivatives [adefovir or tenofovir]). |
Related Information
Primary Sponsor | Hoshino Yuji |
---|---|
Secondary Sponsor | |
Source(s) of Monetary Support | |
Secondary ID(s) | NCT05511779 |
Contact
Public contact | |
Name | Contact for Clinical Tiral information |
Address | 3-2-2 Toranomon, Minato-ku, Tokyo Tokyo Japan 105-0001 |
Telephone | +81-3-5472-1127 |
DL-ClinicalTrials_SyB@symbiopharma.com | |
Affiliation | SymBio Pharmaceuticals Limited |
Scientific contact | |
Name | Yuji Hoshino |
Address | 3-2-2 Toranomon, Minato-ku, Tokyo Tokyo Japan 105-0001 |
Telephone | +81-3-5472-1127 |
DL-ClinicalTrials_SyB@symbiopharma.com | |
Affiliation | SymBio Pharmaceuticals Limited |